Drug Profile
Research programme: nuclear receptor subfamily 1 group F member 3 inverse agonists - Aurigene Oncology
Alternative Names: ROR gamma inverse agonists - Aurigene OncologyLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in India
- 28 Jul 2018 No recent reports of development identified for preclinical development in Inflammation in India
- 15 Apr 2016 Research programme: nuclear receptor subfamily 1 group F member 3 inverse agonists - Aurigene is available for licensing as of 15 Apr 2016. www.aurigene.com